Abstract Background Liposomes coated with fibrinogen γ-chain (HHLGGAKQAGDV, H12) peptide and encapsulating adenosine-diphosphate (ADP) [H12-(ADP)-liposomes] can augment platelet aggregation via glycoprotein IIb/IIIa receptors displayed on activated platelets. H12-(ADP)-liposomes release ADP, which is metabolized into adenosine that has tissue-protective effects. This study evaluated the life-saving efficacy of post-treatment with H12-(ADP)-liposomes in rats with LPS-induced coagulopathy and critical organ injuries. Methods LPS (10 mg/kg) was administered intraperitoneally to rats. The rats were then treated with an intravenous injection of either H12-(ADP)-liposomes or normal saline (vehicle control) 4 h later. Results Post-treatment with H12-(ADP)-liposomes significantly shortened the coagulation time compared to the vehicle treatment at 8 h after LPS challenge and reduced expression of CD62P, a marker of platelet activation, on CD61+ platelets at 12 h. H12-(ADP)-liposome post-treatment also normalized the elevated levels of neutrophil elastase (complex) at 6–24 h and citrullinated histone H3 in bronchoalveolar lavage fluid at 24 h. H12-(ADP)-liposome-treated rats showed reductions in the pathological injury score for the lungs and kidneys at 8 h. The survival rates of rats given H12-(ADP)-liposomes were markedly improved 24 h after LPS challenge relative to vehicle-treated rats (50% vs. 21%, p = 0.038). Conclusions These findings suggest that post-treatment with H12-(ADP)-liposomes ameliorates LPS-induced coagulopathy and neutrophil activation, thereby improving critical organ injuries and survival in LPS-challenged rats.
We report a rare case of giant hepatocellular carcinoma (HCC) with direct invasion to the colon and synchronous multiple lung metastases that achieved complete remission with surgical hepatectomy followed by chemotherapy with atezolizumab and bevacizumab. An 80-year-old man presented with abdominal distension and appetite loss. Imaging studies demonstrated a large HCC protruding from the liver with compression and invasion of the ascending colon, accompanied by multiple bilateral pulmonary nodules. To relieve symptoms and reduce the risk of tumor rupture, upfront surgical resection consisting of right hepatectomy and right hemicolectomy was performed. Histopathological examination revealed moderately to poorly differentiated HCC with direct invasion into the ascending colon and microscopic portal vein invasion. Postoperatively, tumor markers initially decreased; however, subsequent elevation led to initiation of atezolizumab plus bevacizumab for treatment of pulmonary metastases. Tumor markers subsequently normalized, and follow-up computed tomography demonstrated disappearance of all pulmonary metastases, with only scar-like lesions remaining. Radiologic complete remission was achieved 14 months after hepatectomy. The patient remains alive without recurrence 54 months after surgery. Direct invasion of HCC into adjacent organs is extremely rare and is generally associated with poor prognosis. The role of systemic chemotherapy after reduction surgery for advanced HCC remains controversial. Although this is a single case experience and caution is needed when generalizing, this case suggested that combined treatment with initial resection of the primary tumor followed by immunotherapy for remnant lesions could be feasible in selected patients and would potentially contribute to symptom relief and control of metastatic lesions.
Pyloromyotomy is a technique for relieving infantile hypertrophic pyloric stenosis and is performed almost safely without severe complications during long-term outcomes. To the best of our knowledge, this is the first reported case of pancreatic cancer arising from the pancreatic parenchyma embedded within the pyloric ring after neonatal pyloromyotomy. A 39-year-old woman with a history of infantile hypertrophic pyloric stenosis underwent a pyloromyotomy during the neonatal period and presented with progressive nausea and vomiting. Imaging studies suggested the presence of ectopic pancreatic or gastric cancer invading the pancreas. After laparotomy, tumor invasion of the pancreatic head was identified; therefore, pancreaticoduodenectomy was performed. Pathological examination confirmed pancreatic cancer arising from the pancreatic parenchyma embedded within the duodenal and pyloric muscle layers. The patient completed 6 months of adjuvant chemotherapy with oral S-1. Peritoneal dissemination was observed 23 months postoperatively. Abnormal embedding of the pancreatic head in the walls of the duodenum and pyloric ring was considered to be related to neonatal pyloromyotomy. This alteration requires careful preoperative evaluation and flexible surgical planning to achieve curative resection of atypical presentations of gastrointestinal malignancies. The cancer in the present case may be associated with long-term anatomical alterations following neonatal pyloromyotomy, although a direct causal relationship cannot be established.
At present, no clinical guidelines have been established regarding the use of radiofrequency ablation (RFA) for early stage breast cancer. The Radiofrequency Ablation Therapy for Early Breast Cancer as Local Therapy (RAFAELO) study aimed to assess the efficacy and safety of RFA as an alternative to partial mastectomy in patients with early stage breast cancer. This study was a multicenter, single-arm, phase 3 study. Female patients with a single breast cancer classified as Tis–T1 (tumor size ≤ 1.5 cm), N0M0 Stage 0–I underwent treatment RFA. All patients then received radiation therapy totaling 45–60 Gy. The primary endpoint was the 5-year ipsilateral breast tumor recurrence-free survival (IBTRFS) rate. The threshold for a clinically unacceptable 5-year IBTRFS rate was set at 90
Introduction:Primary myelofibrosis (MF) is characterized by MF, splenomegaly, and extramedullary hematopoiesis. MF initially presents with reticular fibers (RFs) and progresses to increased collagen fiber deposition in the advanced stages. Although recent clinical trials have adopted MF improvement as an evaluation criterion, current diagnostic methods rely primarily on qualitative assessments based on the presence or absence of reticular and collagen fibers. Therefore, detecting subtle changes during the early stages of MF can be challenging. Methods:We developed a novel deep learning-based method for quantitatively evaluating MF by measuring RFs as an indicator. Unlike collagen fibers, RFs are detectable from the early stages of MF and increase as the disease progresses. Moreover, based on the hypothesis that splenic fibrosis progresses in parallel with MF, we applied this method to evaluate RFs in the spleen. Using these methods, we analyzed temporal changes in fibrosis, splenomegaly, and hematopoietic stem cell dynamics over time in two MF models: a drug-induced fibrosis model using romiplostim and a Jak2V617F gene-transformed mouse. Additionally, we examined correlations between our quantitative fibrosis measurements and clinical data, including MF grade and genetic mutations. Results:Our findings revealed that in Jak2V617F gene-transformed mice, splenomegaly and extramedullary hematopoiesis in the spleen occurred earlier than MF. Furthermore, the quantitative fibrosis method significantly correlated with MF grade in patients with myeloproliferative neoplasms and the JAK2V617F mutant allele burden. Conclusion:Our novel deep learning-based method successfully captured temporal changes in bone marrow and spleen fibrosis and shows potential for clinical application. Trial Registration:The authors have confirmed clinical trial registration is not needed for this submission.